Compounded Semaglutide: What It Is and Is It Safe?

Compounded semaglutide is semaglutide prepared by a compounding pharmacy rather than by the maker of an FDA-approved product. It is not FDA approved, which means the FDA does not review it for safety, effectiveness or quality before it is sold ^[1][2][4]. Compounded versions are commonly sold as multiple-dose vials that patients draw from with a syringe, and sometimes as prefilled syringes, rather than the prefilled pens used for approved injectable semaglutide ^[1][4].

Whether it is “safe” depends on what is being compared. The FDA’s position is that compounded drugs pose a higher risk to patients than FDA-approved drugs because they skip premarket review, and that they should only be used when a patient’s medical needs cannot be met by an available FDA-approved drug, or when the approved drug is not commercially available ^[1][4]. The best-documented harms tied to compounded semaglutide specifically are dosing errors — some patients have injected 5 to 20 times the intended dose, with some cases requiring hospitalization ^[1][4].

What is compounded semaglutide, and how is it different from an approved pen?

Under section 503A of the FDCA, human drug products compounded by a licensed pharmacist in a state-licensed pharmacy or a federal facility, or by a licensed physician, qualify for exemptions from certain FDA requirements ^[6]. A compounded drug is not FDA approved, and the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed ^[1][2][4].

There are currently three FDA-approved semaglutide products ^[4]:

Product	Form	How it is taken
Wegovy	Single-dose prefilled pens that deliver a preset dose	Once weekly injection [4]
Ozempic	Multiple-dose prefilled pens for single-patient use	Once weekly injection [4]
Rybelsus	Oral tablets	Daily [4]

Approved injectable semaglutide is dosed in milligrams, comes in standard concentrations, and is available only in prefilled pens ^[4]. Compounded versions differ on all three counts. Compounders sell semaglutide in multiple-dose vials for self-administration and sometimes in prefilled syringes; concentrations vary by compounder, and a single compounder may offer several concentrations ^[1][4]. Instructions that come with compounded products, when provided, may direct dosing in “units” rather than milligrams or milliliters — and the volume of a “unit” varies with the concentration ^[4].

The FDA says compounded drugs should only be used for patients whose medical needs cannot be met by an available FDA-approved drug, or when the approved drug is not commercially available ^[1][4]. The agency also says patients should get a prescription from their doctor and fill it at a state-licensed pharmacy ^[1].

Is compounded semaglutide the same drug as Ozempic or Wegovy?

No, and the FDA has taken enforcement action over that exact claim. On September 9, 2025, the FDA sent a warning letter to Hims & Hers Health, Inc. dba Hers, addressed to CEO Andrew Dudum, over content reviewed on forhers.com in August 2025 ^[3]. The letter cited claims including “Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients” ^[3].

The FDA found that these claims imply the product is the same as an FDA-approved product when it is not, making it misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act ^[3]. The company was given 15 working days to respond ^[3].

More broadly, the FDA lists these as false or misleading claims when telehealth companies promote compounded GLP-1s ^[2]:

• Describing a compounded drug as a generic version of an FDA-approved drug, or the same as one. Generic drugs are FDA approved before marketing; compounded drugs are not ^[2].
• Claiming a compounded drug has been FDA approved or evaluated for safety and effectiveness ^[2].
• Describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug ^[2].
• Claiming the product is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. The FDA does not approve or license any compounding facility ^[2].
• Using branding that falsely implies the telehealth company itself is the compounder ^[2].

What are semaglutide sodium and semaglutide acetate?

These are salt forms of semaglutide sold by some compounders, and they are different active ingredients from the base form of semaglutide used in the approved drugs ^[1][4]. The FDA has stated it has no information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved products, and the agency is not aware of any lawful basis for their use in compounding ^[1][4].

Compounders may also add other ingredients to their semaglutide products. The FDA has seen products containing cyanocobalamin (vitamin B12), pyridoxine (vitamin B6), levocarnitine, and nicotinamide adenine dinucleotide (NAD). The safety and effectiveness of combining semaglutide with these ingredients has not been established ^[4].

Why are dosing mistakes more likely with a vial than a pen?

Wegovy’s single-dose pens deliver a preset dose, and Ozempic’s pens are also prefilled, so there is little for the patient to measure ^[4]. Compounded semaglutide in a multiple-dose vial requires the patient to draw the right amount into a syringe, and that step is where errors have happened ^[4][5].

The FDA has received adverse event reports, some requiring hospitalization, tied to overdoses from dosing errors with compounded injectable semaglutide. The errors came from two directions: patients measuring and self-administering incorrect doses, and clinicians miscalculating doses when converting between milligrams, milliliters and “units” ^[1][4].

In the reports involving patients drawing from multi-dose vials, patients administered 5 to 20 times the intended dose ^[4]. In several reports, patients were told to use a U-100 (1 milliliter) insulin syringe to draw small doses — for example, a 5-unit (0.05 mL) dose — and mistakenly administered 50 units instead ^[4].

Provider-side errors show the same pattern. In one reported case, a provider intended a 0.25 mg dose (5 units) but prescribed 25 units, so the patient received five times the intended dose and experienced severe vomiting. In another, a provider prescribed 20 units instead of 2 units, affecting three patients who each received 10 times the intended dose and experienced nausea and vomiting ^[4].

Many of the affected patients had no prior experience with self-injection, and confusion among milliliters, milligrams and “units” contributed to the errors ^[4]. A peer-reviewed poison-center case series published in the Journal of the American Pharmacists Association in 2023 described three cases of adverse drug events after incorrect administration of semaglutide obtained from compounding pharmacies and an aesthetic spa; two patients made 10-fold dosing errors, and all experienced nausea, vomiting and abdominal pain, with most symptoms lasting for days. One of those patients received a vial with syringes and no pharmacist counseling, and one was dosed in milliliters and units rather than milligrams ^[5].

Reported overdose effects include nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones ^[4]. Because semaglutide has a half-life of about one week, a prolonged period of observation and treatment for overdose symptoms may be necessary ^[4].

The FDA has also received reports of compounded semaglutide prescribed in doses beyond what the FDA-approved label contains — more product per dose, more frequent dosing, or faster increases — with some of these events serious enough that patients sought medical attention ^[1].

Have compounded semaglutide products been recalled?

Yes. Two large recalls have affected compounded semaglutide:

Recall	Company and location	Scope	Reason given	Dates
Compounded semaglutide injection, multidose vials	ProRx LLC, Exton, Pennsylvania	More than 36,000 vials, distributed in Texas and Utah	Lack of sterility assurance; no contamination was confirmed	Initiated October 15, 2025; classified Class II on October 27, 2025 [7]
Compounded semaglutide and semaglutide with glycine, multidose vials	Apollo Care, LLC, Columbia, Missouri (an FDA-registered 503B outsourcing facility)	156,611 vials of compounded semaglutide plus 5,500 vials of semaglutide with glycine, distributed nationwide	Particulate matter identified as nylon/polyamide and silk/proteinaceous-type material	Initiated July 29, 2026 [8]

A Class II recall means the product may cause temporary or medically reversible adverse health effects, with the probability of serious injury remote ^[7].

What have FDA inspections of compounding facilities found?

The FDA sent a warning letter dated April 2, 2025 to Empower Clinic Services LLC dba Empower Pharmacy of Houston, Texas, after an inspection from September 24 to October 4, 2024. Investigators found inadequate environmental monitoring in the critical aseptic area, media fills that were not run under the most challenging conditions, and failure to sterilize the stopper sorting bowl, supply hopper and insertion station in the ISO 5 area. The FDA concluded that drug products intended to be sterile were prepared under insanitary conditions and were adulterated under section 501(a)(2)(A) of the FDCA ^[6].

Apollo Care had also received an FDA warning letter in February 2026 over sterility concerns and insanitary conditions found during a 2025 inspection, which noted “white, fiber-like particles and debris” ^[8].

How long can a compounded semaglutide vial be used, and how should it be stored?

For vials in use at home, the FDA recommends discarding any multiple-dose sterile vial within 28 days after first use, even if medication remains and even if the compounder’s instructions say it can be used longer, because contamination risk rises after 28 days. The agency also says to use a new sterile needle and syringe for every dose, since reuse can contaminate the medication ^[1].

Injectable GLP-1s require refrigeration, and the FDA says not to use a product that arrives warm or with insufficient ice packs, as this can affect the drug’s quality ^[1].

How many adverse events have been reported, and are those numbers complete?

As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide ^[1]. Those counts are likely an undercount: federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to the FDA ^[1].

The reports also have limits. The FDA notes it is not always possible to determine whether a drug directly caused a reported event or whether other factors contributed, and many of the reported events for compounded products appear consistent with the adverse events of the FDA-approved versions ^[1]. Adverse events and medication errors can be reported to the FDA’s MedWatch program online, or by downloading the form and faxing it to 1-800-FDA-0178 ^[4].

What about counterfeit and fraudulent products?

The FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the US with false label information. In some cases, the pharmacies named on the labels do not exist; in others, the label names a licensed pharmacy that, based on information the FDA gathered, did not compound the product. The agency is aware of one reported adverse event tied to a product labeled as compounded tirzepatide from a pharmacy that did not make it: redness, swelling, pain and a red lump at the injection site ^[1].

The FDA is also aware of counterfeit Ozempic in the US drug supply chain. Counterfeits may contain the wrong ingredients, or too little, too much or no active ingredient at all ^[1]. On the import side, the agency established a “green list” import alert (66-80) to stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the US supply chain. That alert does not restrict legal compounding or imports from API manufacturers that appear to be in compliance based on FDA inspection or evaluation ^[1].

What about “research peptides” and ingredients that cannot lawfully be compounded?

Two ingredients sometimes marketed to consumers — retatrutide and cagrilintide — cannot be used in compounding under federal law. They are not components of FDA-approved drugs and have not been found safe and effective for any condition ^[1].

The FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers. The agency has also warned active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities for repackaging retatrutide ^[1].

What red flags should I check before buying online?

The FDA lists these warning signs when buying compounded GLP-1s through telehealth ^[1]:

• Claims that the compounded drug is the same as an FDA-approved drug ^[1]
• Deep discounts or prices that seem too good to be true ^[1]
• Medicine that looks different from previous fills or from the website’s photos, or that arrives in broken or damaged packaging or without instructions for use ^[1]
• No screening and prescription by a licensed doctor before the medicine is provided ^[1]
• No licensed doctor available to answer questions afterward ^[1]
• Spelling errors on the label or an incorrect pharmacy address ^[1]
• A pharmacy name on the label that may be fraudulent ^[1]

The FDA’s BeSafeRx campaign is the agency’s resource for buying prescription medicines online safely ^[1]. Questions about instructions for use or label information should go to the compounder that made the drug or the telehealth platform where it was purchased ^[1].

What questions should I ask a prescriber or pharmacy?

The FDA encourages patients to talk with their health care provider or compounder about how to measure and administer the intended dose ^[1][4]. Questions worth asking, based on the agency’s own guidance:

• What exact form of semaglutide is in the vial — the base form or a salt such as semaglutide sodium or semaglutide acetate — and are any other ingredients, such as B12 or glycine, included? ^[1][4][8]
• What is the concentration, what syringe size fits the intended dose, and how is the dose measured with that syringe? The FDA asks compounders and providers to supply both the right syringe and counseling on measuring ^[4].
• When must the vial be discarded? The FDA’s recommendation is 28 days after first use ^[1].
• Who is the compounder — a 503A state-licensed pharmacy or a registered 503B outsourcing facility? Their reporting duties differ, and federal law does not require non-outsourcing-facility pharmacies to report adverse events to the FDA ^[1][8].
• What should happen if a shipment arrives warm or with insufficient refrigeration? ^[1]

Sources

1. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
2. US Food and Drug Administration. FDA to telehealth companies: what to know when promoting compounded drugs.
3. US Food and Drug Administration. Warning letter: Hims & Hers Health, Inc. dba Hers. September 9, 2025.
4. US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.
5. PubMed. Administration errors of compounded semaglutide reported to a poison control center—case series.
6. US Food and Drug Administration. Warning letter: Empower Clinic Services, LLC dba Empower Pharmacy. April 2, 2025.
7. HMP Global Learning Network. Class II recall for ProRx semaglutide injections due to lack of sterility assurance. October 30, 2025.
8. MedShadow Foundation. FDA recalls and warnings: foreign particles found in compounded semaglutide, cancer-causing impurities in bladder drug. August 13, 2026.
9. US Food and Drug Administration. Compounding: inspections, recalls, and other actions.
10. Drug Discovery and Development. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide.
11. US Food and Drug Administration. Warning letter: Gram Peptides. March 31, 2026.
12. PubMed. Ability of adults to correctly use grey market peptide semaglutide GLP-1 receptor agonists acquired without a prescription.
13. GoodRx. Microdosing GLP-1s: does it work? Risks and benefits.
14. Cleveland Clinic. Should you microdose GLP-1 medications? July 31, 2026.
15. Rheumatology Advisor. Direct-to-consumer telehealth companies: what clinicians should know.